Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2022-12-21 00:00:00 ET · period of report 2022-12-21 · accession 0001209191-22-062377 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-12-21 | 2022-12-21 | BBIO | Kumar Neil | CEO, Pres, Dir | S - Sale | — | -200.0K | 995.7K | -17% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-21 | S | D | 200,000 | — | 995,686 | I See Footnote | — | — | (F1) The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $8.26 per share for the purposes of determining the number of shares of the exchange fund issuable to the reporting person. (F2) The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |